ATLANTA & EDINBURGH, Scotland--(BUSINESS WIRE)--Oct. 6, 2005--Serologicals Corporation (NASDAQ: SERO) announced today that Chemicon International, Inc., its wholly-owned subsidiary, and Stem Cell Sciences Holdings LTD (SCS), have signed an exclusive agreement to manufacture and market novel patent-protected embryonic stem (ES) cell media for the research market. Under the terms of this agreement, SCS will transfer the patented technology and expertise to Chemicon to allow it to manufacture a fully formulated cell culture media that Chemicon will exclusively market worldwide.